Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Targeting histone deacetylase to overcome resistance of BRAFV600E melanoma cells to apoptosis ASCO June, 2011
2. Targeted therapy in melanoma. Present and future European Association of Dermato-Oncology, Nantes, France June, 2011
3. Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) & nbsp; on BRAF inhibitors (BRAFi).” ASCO June, 2011
4. BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with <I>BRAF</I> V600E mutation-positive metastatic melanoma ASCO June, 2011
5. HDAC Inhibitors for treatment of BRAF inhibitor resistance International Melanoma Working Group, Barcelona, Spain April, 2011
6. Where next in immunotherapy of melanoma Cancer Symposium, Wellington, New Zealand February, 2011
7. Induction of apoptosis by selective BRAF inhibitors: The key to therapeutic success? Society for Melanoma Research, Sydney November, 2010
8. Advances in melanoma diagnosis and targeted therapy Melanoma Centres Meeting, Sydney November, 2010
9. Adjuvant therapy of melanoma – What lies ahead Melanoma Centres Meeting, Sydney November, 2010
10. Induction of apoptosis in melanoma cells Queenstown Molecular Biology Meeting, Queenstown, New Zealand September, 2010
11. The immune system and cancer Medical Oncology Group Australia, Sydney, NSW August, 2010
12. Induction of apoptosis in human melanoma. The key to therapeutic success? ASCO, Chicago, IL June, 2010
13. Global Melanoma Task Force Global Melanoma Task Force”, Seoul May, 2010
14. International Melanoma Working Group Lansdowne, Virginia May, 2010
15. BRAF Inhibitors and New Melanoma Treatments North Coast Cancer Conference, Ballina, NSW March, 2010
16. Proapoptotic treatment approaches in metastatic melanoma Third world meeting of interdisciplinary melanoma skin cancer centres. Berlin November, 2009
17. Immunotherapy Symposium MOGA 30th Anniversary Meeting, Canberra, ACT August, 2009
18. Apoptosis Mediators 7th world congress on melanoma . Vienna May, 2009
19. Allogeneic Vaccines 7th world congress on melanoma . Vienna May, 2009
20. Metabolic Approaches to Treatment of Melanoma Second World Meeting on Melanoma Cancer Centers, Florida, USA November, 2008
21. New Insights in Drug Resistance in Melanoma” and (2) “Targeting Apoptosis in Melanoma Perspectives in Melanoma XII, The Hague, Netherlands October, 2008
22. Targeting Histone Deacetylase and DNA Methylation International Conference on Adjuvant Treatment of Melanoma. Marseille, France June, 2008
23. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Poster Presentation 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago. Kirkwood, J.M., Lorigan, P., Hersey, P., et al May, 2008
24. Global Melanoma Task Force “Global Melanoma Task Force”, Vienna April, 2008
25. Immunoregulation and Metastasis 6th Biennial International Sentinel Node Society, Sydney February, 2008
26. Global Melanoma Task Force Global Melanoma Task Force”, Rome December, 2007
27. ER stress and LDH in melanoma. Part of the same spectrum COSA, Adelaide November, 2007
28. Apoptosis Induction and Immunotherapy Society for Biological Therapy of Cancer November, 2007
29. New treatments for metastatic melanoma COSA, Adelaide November, 2007
30. International Melanoma Working Group Huntington Beach, California October, 2007
31. Melanoma vaccination with cell line derived antigens First World Meeting of Interdisciplinary Melanoma, Barcelona September, 2007
32. Global Melanoma Task Force “Global Melanoma Task Force”, Reykjavik July, 2007
33. Current Status of DC Vaccine Trials in the Sydney Melanoma Unit MMRI Dendritic Cell Symposium.Brisbane June, 2007
34. International Melanoma Working Group “International Melanoma Working Group”, Florence May, 2007
35. AACR, Los Angeles April, 2007
36. Induction of Death Receptors for TRAIL by ER Stress “Global Melanoma Task Force”, Paris February, 2007
37. Host Cell Interactions and Response to the Cancer Cell" Poster – “Induction of death receptors for TRAIL by agents which induce the ER stress response”. Keystone Symposium .Keystone, Colorado, USA January, 2007
38. Induction of Death Receptors for TRAIL by ER Stress ASI, Auckland, New Zealand December, 2006
39. Induction of death receptors for TRAIL by ER Stress ASI, Auckland, New Zealand December, 2006
40. 18th EORTC–NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague November, 2006
41. Hurdles to overcome in treatment of melanoma by TRAIL Society for Biological Therapy, Los Angeles October, 2006
42. How Effective will TRAIL be in Treatment of Melanoma? Newcastle HMRI Conference on Translational Cancer Research September, 2006
43. Rose Bengal induces dual modes of cell death and has clinical activity against melanoma Perspectives in Melanoma, Noordwijk, Netherlands September, 2006
44. Melanoma cells resistant to TRAIL are more vulnerable to necrotic death induced by Cisplatin AACR, Washington. Poster April, 2006
45. TRAIL Biology and Melanoma Keystone Symposia,Sante Fe, USA January, 2006
46. Present status of immunotherapy for metastatic melanoma COSA, Brisbane November, 2005
47. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, - dacarbazine (DTIC) in patients with metastatic melanoma (MM).” COSA, Brisbane November, 2005
48. Selection of Melanoma Cells by the Immune System for Resistance to Apoptosis Canbio Meeting, Adelaide, S.A September, 2005
49. Allogeneic Vaccines in Treatment of Melanoma 6th World Congress of Melanoma, Vancouver, Canada September, 2005
50. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-552, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, + dacarbazine (DTIC) in patients with metastatic melanoma (MM) 41st ASCO Annual Meeting, Orlando, Florida, USA May, 2005
51. Understanding resistance of melanoma to apoptosis AACR, Anaheim, California. Poster April, 2005
52. Sensitization of Melanoma to Apoptosis Hunter Area Pathology Service April, 2005
53. Cross resistance of melanoma to apoptosis induced by TRAIL and chemotherapy Regulation of Cell Death in Oncogenesis, Hawaii. Presentation January, 2005
54. Sensitisation of melanoma to apoptosis Inaugural Meeting of Australian Dermatology Research Association, Sydney May, 2004
55. How melanoma cells evade TRAIL induced apoptosis Keystone Symposia March, 2004
56. 5th International Conference on the Adjuvant Therapy of Malignant Melanoma “5th International Conference on the Adjuvant Therapy of Malignant Melanoma”, Athens, Greece March, 2004
57. Perspectives in Melanoma VI Miami, Florida, USA November, 2003
58. Perspectives in melanoma management European Conference,The Netherlands October, 2003
59. Overcoming resistance of melanoma cells to apoptosis First Annual Melanoma Research Congress,Philadelphia June, 2003
60. State of the Science Meeting – Turning Scientific Discoveries into Clinical Targets National Cancer Institute January, 2003
61. Understanding resistance of melanoma to TRAIL induced apoptosis Fourth International Conference on Adjuvant Treatment of Melanoma. London March, 2002
62. Immune Monitoring of Cancer Patients Workshop sponsored by the Society for Biological Therapy. National Cancer Institute, USA November, 2001
63. Evolution of melanoma as a model for biological therapy Society for Biological Therapy, San Francisco November, 2001
64. Adjuvant Treatment of Melanoma Surgical Oncology Group of the Royal Australian College of Surgeons, Canberra May, 2001
65. Results of a Randomised Trial of Immunotherapy in Patients with Stage IIb and III Melanoma 5th World Conference on Melanoma, Venice March, 2001
66. Perspectives in Vaccine Treatment of Melanoma 5th World Conference on Melanoma, Venice March, 2001
67. Gordon Ada Lecture “Immunology of Melanoma”, Australian Society of Immunology, December, 2000
68. Perspectives in Melanoma Pittsburgh, Pennsylvania June, 2000
69. Melanoma Cells in the Circulation Australasian College of Dermatologists, May, 2000
70. Presentation – “Does the immune system select for apoptotic resistance in melanoma cells? Visiting Professor, Department of Medicine and Surgery, UCLA Medical Centre, Los Angeles April, 2000
71. Cell death mechanisms and Cancer Therapy AACR,San Diego February, 2000
72. Regulation of TRAIL Induced Apoptosis of Melanoma Keystone Symposia, Santa January, 2000
73. Regulation of TRAIL Induced Apoptosis of Melanoma Third Peter Mac Symposium, Melbourne November, 1999
74. Clinical Relevance of Micrometastasis Detection International Symposium on Detection and Relevance of Micrometastases, Hamburg, Germany September, 1999
75. Vaccinia Melanoma Cell Lysates in Immunotherapy of Patients with Stage IIb and III Melanoma 3rd International Conference on The Adjuvant Therapy of Melanoma, London, March, 1999
76. TRAIL Induced Apoptosis of Melanoma 3rd International Conference on The Adjuvant Therapy of Melanoma, London March, 1999
77. New Insights into Vaccine Treatment of Melanoma 1st International Symposium on Melanoma, Rome June, 1998
78. Adjuvant Treatment of Melanoma 19th World Congress of Dermatology June, 1997
79. Adjuvant Treatment of Melanoma 4th World Conference on Melanoma June, 1997
80. Vaccines in Treatment of Melanoma Bruce Cain Memorial Lecturer, “Vaccines in Treatment of Melanoma”, New Zealand Society for Oncology, Palmerston, New Zealand May, 1997
81. Gene Delivery Systems OECD Workshop on "Gene Delivery Systems", Ottawa, Canada June, 1995
82. Molecular Advances in Melanoma Diagnosis and Treatment Symposium "Molecular Advances in Melanoma Diagnosis and Treatment", Pittsburgh February, 1995
83. The Influence of Different Cytokines on T cell Responses to Tumor Cells Annual Meeting of the International Society for Interferon Research October, 1994
84. Effects of Ultraviolet Radiation (UVR) on the Human Immune System Australian Society for Experimental Pathology Annual Scientific Meeting September, 1994
85. Immunobiology of melanoma progression" "Current status of melanoma vaccine trials in Australia International Melanoma Conference, Brisbane April, 1994
86. Effects of solar radiation on the human immune system UV Monitoring and Assessment Program Panel, Miami, Florida March, 1994
87. Active immunotherapy following surgical removal of high risk melanoma. Present status and future prospects COSA 20th Annual Scientific Meeting, Perth, Western Australia November, 1993
88. Active immunotherapy following surgical removal of high risk melanoma. Present status and future prospects Society for Biological Therapy, Nashville, Tennessee November, 1993
89. Viral oncolysates in treatment of melanoma New York Academy of Science Sponsored Conference, Specific Immunotherapy of Cancer with Vaccines, Washington DC January, 1993
90. Melanoma antigens recognized by T cells International Consensus Conference on Human Melanoma Antigens, Lausanne, Switzerland November, 1992
91. MHC restricted recognition of melanoma by cytotoxic T cells Keystone Symposia, Taos, New Mexico February, 1992
92. Advances in the biology and clinical management of melanoma Advances in the biology and clinical management of melanoma,Houston November, 1991
93. Effects of UV-A on natural killer (NK) cell activity, antigen presenting cells (APC) and induction of suppressor cells 19th Annual Meeting of the American Society for Photobiology, San Antonio, Texas June, 1991
94. Active Specific Immunotherapy of Melanoma 2nd International Meeting on Melanoma held in Venice October, 1989
95. T cell responses in patients with melanoma Salk Research Clinic, La Jolla, California, USA January, 1989
96. Active immunotherapy with viral oncolysates". Invited as General Motors Visiting Professor to Symposium Tumor specific antigens and active specific immunotherapy in man" University of South California, Cancer Center, Los Angeles December, 1988
97. Recombinant interferon alpha (2A) combined with dacarbazine in treatment of metastatic melanoma. ISIR-TNO Meeting, Helsinki January, 1986
98. Current status and future prospects for immunotherapy of melanoma Symposium: "Update in Cellular and Tumor Immunology", Meeting of the Canadian Society for Clinical Investigation, Vancouver, B.C September, 1985
99. Effects of recombinant leukocyte interferon (rIFN-aA) on tumor growth and immune responses in patients with metastatic melanoma". Symposium: "Developments in the treatment of malignant and viral disorders with recombinant interferon", 14th International Chemotherapy Congress, Osaka, Japan, June, 1985
100. Effects of ultraviolet irradiation on the immune system in man Second World Congress on Skin Cancer, New York, March 1985. Skin Cancer Foundation, New York January, 1985
101. Cell mediated immunity in cancer patients Symposium: "Immunological evaluation of the cancer patients", 13th International Cancer Congress, Seattle January, 1982
102. The role of natural killer cells against tumours Symposium: "Effector mechanisms against tumours", Manchester January, 1979
103. WHO Program Committee Meeting, Brno, Czechoslovakia January, 1979



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Data for drug discovery Advances and Progress in Drug Design February, 2012
Adjuvant therapies for melanoma | new promises Skin Cancer Conference August, 2011

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.